New Hope for Deadly Clotting Disorder as Cadrenal Drug Shows Promise Despite Trial Setback

PONTE VEDRA, FL – February 24, 2026 – In a development that underscores the complex path of drug discovery, Cadrenal Therapeutics announced encouraging Phase 2 results for its investigational drug, CAD-1005, for the treatment of Heparin-Induced Thrombocytopenia (HIT), a life-threatening complication of heparin therapy. While the drug did not meet its pre-specified primary goal, a compelling reduction in dangerous blood clots has prompted the company to advance the program, scheduling a pivotal End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for March 2026.

The announcement highlights a crucial learning moment in the fight against HIT: the initial measure of success may have been misplaced. The results suggest that CAD-1005, by targeting the root immunological cause of the disease, could represent a significant leap forward from current treatments that only manage its symptoms.

A Tale of Two Endpoints

The randomized, placebo-controlled Phase 2 trial was designed to evaluate the safety and efficacy of CAD-1005 in patients with suspected HIT. The original primary endpoint, chosen by the drug's previous sponsor, Veralox Therapeutics, was the rate of platelet count recovery. However, the study, which analyzed data from 24 patients, found no significant difference in platelet recovery between the CAD-1005 and placebo groups.

Ordinarily, missing a primary endpoint can be a major blow to a drug's development. But in this case, the secondary endpoint data told a far more compelling story. The trial revealed a starkly high rate of thrombotic events—the blood clots that make HIT so deadly—in the placebo group, with over 75% of patients experiencing new or worsening clots despite receiving standard anticoagulant therapy. In contrast, the group receiving CAD-1005 saw this rate fall to 50%, an absolute reduction of more than 25%.

This outcome has led Cadrenal to conclude that platelet count recovery is not a reliable surrogate for clinical benefit in HIT. Thrombotic events continued to occur in patients even after their platelet counts had normalized, suggesting that simply restoring platelets does not solve the underlying problem.

“We learned two very important things from this study, the only blinded placebo-controlled trial ever conducted in HIT,” said James Ferguson, MD, Chief Medical Officer of Cadrenal Therapeutics. “First, platelet count recovery was not an appropriate surrogate endpoint for clinical efficacy in a trial in which standard therapy event rates were strikingly high. Secondly, despite the relatively small number of patients, the reduction in thrombotic events with CAD-1005 is extremely encouraging.”

Addressing a Critical Unmet Need

Heparin is one of the most widely used drugs in hospitals, administered to over 12 million patients in the United States annually to prevent blood clots. For a small but significant number of these patients, the therapy backfires, triggering HIT. This paradoxical condition occurs when the immune system creates antibodies that activate platelets, leading to a storm of clotting throughout the body while simultaneously depleting the platelet supply.

The consequences are severe, including deep vein thrombosis, pulmonary embolism, stroke, and limb amputation. Mortality rates for HIT can exceed 20%, and even with treatment, the risk of new thrombotic events remains dangerously high.

Current standard-of-care involves immediately stopping all heparin products and starting an alternative, non-heparin anticoagulant like argatroban. However, these therapies only address the downstream clotting cascade; they do nothing to stop the underlying immune reaction that drives the disease. Furthermore, these potent anticoagulants carry a significant risk of causing major bleeding, forcing clinicians to walk a fine line between preventing clots and causing hemorrhage.

“Our field (HIT) is full of anticoagulant use in the absence of randomized prospective trials,” noted Steven E. McKenzie, MD, PhD, a Professor of Medicine at Thomas Jefferson University and a member of the study's steering committee. This highlights the urgent need for therapies that are not only effective but also proven through rigorous, controlled studies.

A Novel Mechanism of Action

This is where CAD-1005 aims to create a new paradigm. As a first-in-class selective inhibitor of 12-lipoxygenase (12-LOX), it is the only therapy in clinical development that targets the core immune mechanism of HIT. The 12-LOX enzyme is a key part of the inflammatory pathway that leads to platelet activation and consumption in HIT. By blocking this pathway, CAD-1005 is designed to stop the disease at its source, rather than just managing its consequences.

This unique approach could potentially reduce the risk of thrombosis without the high bleeding risk associated with traditional anticoagulants. Preclinical studies and data from healthy human volunteers have shown that the drug does not appear to increase bleeding.

“The encouraging trend toward reduced thrombotic events in the CAD-1005 treatment arm is strong support for the company’s decision to acquire this asset and rapidly progress its development,” stated Quang X. Pham, CEO of Cadrenal Therapeutics. “Inhibition of 12-LOX is an exciting therapeutic frontier, potentially targeting numerous inflammatory, thrombotic, and metabolic conditions.”

The Path Forward: A High-Stakes FDA Meeting

With these encouraging, albeit complex, results in hand, Cadrenal is making a strategic pivot. The company is betting that the FDA will agree that reducing life-threatening thrombotic events is a more clinically meaningful endpoint than the rate of platelet recovery. The upcoming End-of-Phase 2 meeting is a critical step to align on a registration path for a larger Phase 3 trial.

Bolstering Cadrenal's position are the Fast Track and Orphan Drug designations granted to CAD-1005 by the FDA, as well as its orphan status in Europe. These designations are reserved for drugs that treat serious conditions and fill a significant unmet medical need, and they provide a framework for more frequent communication with the agency and a potentially expedited review process.

Success at this meeting would allow Cadrenal to design a pivotal Phase 3 study focused directly on preventing death, stroke, heart attack, and other thrombotic complications. If successful, CAD-1005 could become the first therapy to directly address the immune-driven cause of HIT, potentially transforming the standard of care. The outcomes of that meeting and the subsequent design of a pivotal trial will be closely watched by clinicians and patients alike, all hoping for a new, more effective weapon against this devastating disorder.